

# Rita Citraro

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/835816/publications.pdf>

Version: 2024-02-01

101  
papers

3,421  
citations

94433

37  
h-index

175258

52  
g-index

102  
all docs

102  
docs citations

102  
times ranked

4145  
citing authors

#	ARTICLE	IF	CITATIONS
1	Antidepressant Drugs for Seizures and Epilepsy: Where do we Stand?. <i>Current Neuropharmacology</i> , 2023, 21, 1691-1713.	2.9	4
2	Colchicine in Managing Skin Conditions: A Systematic Review. <i>Pharmaceutics</i> , 2022, 14, 294.	4.5	22
3	High-Intensity, Low-Frequency Pulsed Electromagnetic Field as an Odd Treatment in a Patient with Mixed Foot Ulcer: A Case Report. <i>Reports</i> , 2022, 5, 3.	0.5	6
4	N-acetylcysteine aggravates seizures while improving depressive-like and cognitive impairment comorbidities in the WAG/Rij rat model of absence epilepsy. <i>Molecular Neurobiology</i> , 2022, , 1.	4.0	8
5	Retrospective Analysis of the Pharmaco-Utilization of VEGF Inhibitors and Health Care Costs among Patients with Wet Age-Related Macular Degeneration and Other Ocular Diseases in Italy. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 2548.	2.6	2
6	Effect of Statins on Lung Cancer Molecular Pathways: A Possible Therapeutic Role. <i>Pharmaceutics</i> , 2022, 15, 589.	3.8	11
7	Epilepsy and Alzheimer's Disease: Current Concepts and Treatment Perspective on Two Closely Related Pathologies. <i>Current Neuropharmacology</i> , 2022, 20, 2029-2033.	2.9	4
8	mGlu3 metabotropic glutamate receptors as a target for the treatment of absence epilepsy: preclinical and human genetics data. <i>Current Neuropharmacology</i> , 2022, 20, .	2.9	3
9	Diamagnetic Therapy in a Patient with Complex Regional Pain Syndrome Type I and Multiple Drug Intolerance: A Case Report. <i>Reports</i> , 2022, 5, 18.	0.5	4
10	Liraglutide chronic treatment prevents development of tolerance to antiseizure effects of diazepam in genetically epilepsy prone rats. <i>European Journal of Pharmacology</i> , 2022, 928, 175098.	3.5	3
11	Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study. <i>Life</i> , 2022, 12, 965.	2.4	4
12	First evidence of altered microbiota and intestinal damage and their link to absence epilepsy in a genetic animal model, the WAG/Rij rat. <i>Epilepsia</i> , 2021, 62, 529-541.	5.1	35
13	Direct Oral Anticoagulants: From Randomized Clinical Trials to Real-World Clinical Practice. <i>Frontiers in Pharmacology</i> , 2021, 12, 684638.	3.5	33
14	Increased efficacy of combining prebiotic and postbiotic in mouse models relevant to autism and depression. <i>Neuropharmacology</i> , 2021, 198, 108782.	4.1	33
15	Disease Modification in Epilepsy: Behavioural Accompaniments. <i>Current Topics in Behavioral Neurosciences</i> , 2021, , 145-167.	1.7	1
16	Oleil Hydroxytyrosol (HTOL) Exerts Anti-Myeloma Activity by Antagonizing Key Survival Pathways in Malignant Plasma Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11639.	4.1	4
17	Asthma Control during COVID-19 Lockdown in Patients with Severe Asthma under Biological Drug Treatment. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 12089.	2.5	1
18	Effects of Histone Deacetylase Inhibitors on the Development of Epilepsy and Psychiatric Comorbidity in WAG/Rij Rats. <i>Molecular Neurobiology</i> , 2020, 57, 408-421.	4.0	53

#	ARTICLE	IF	CITATIONS
19	Modeling poststroke epilepsy and preclinical development of drugs for poststroke epilepsy. <i>Epilepsy and Behavior</i> , 2020, 104, 106472.	1.7	7
20	Butyrate prevents valproate-induced liver injury: In vitro and in vivo evidence. <i>FASEB Journal</i> , 2020, 34, 676-690.	0.5	37
21	Nano-hydrogel embedded with quercetin and oleic acid as a new formulation in the treatment of diabetic foot ulcer: A pilot study. <i>International Wound Journal</i> , 2020, 17, 485-490.	2.9	58
22	IL-6 Receptor Blockade by Tocilizumab Has Anti-absence and Anti-epileptogenic Effects in the WAG/Rij Rat Model of Absence Epilepsy. <i>Neurotherapeutics</i> , 2020, 17, 2004-2014.	4.4	24
23	Pain Modulation in WAG/Rij Epileptic Rats (A Genetic Model of Absence Epilepsy): Effects of Biological and Pharmacological Histone Deacetylase Inhibitors. <i>Frontiers in Pharmacology</i> , 2020, 11, 549191.	3.5	13
24	Pharmacokinetic considerations about antiseizure medications in the elderly. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 983-995.	3.3	9
25	Metabolic Alterations Predispose to Seizure Development in High-Fat Diet-Treated Mice: the Role of Metformin. <i>Molecular Neurobiology</i> , 2020, 57, 4778-4789.	4.0	11
26	HDL (High-Density Lipoprotein) and ApoA-1 (Apolipoprotein A-1) Potentially Modulate Pancreatic $\beta$ -Cell Glucagon Secretion. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 2941-2952.	2.4	10
27	Safety profiles of biologic agents for inflammatory bowel diseases: a prospective pharmacovigilance study in Southern Italy. <i>Current Medical Research and Opinion</i> , 2020, 36, 1457-1463.	1.9	40
28	Neural Modulation of the Primary Auditory Cortex by Intracortical Microstimulation with a Bio-Inspired Electronic System. <i>Bioengineering</i> , 2020, 7, 23.	3.5	6
29	Metabolic and Cognitive Effects of Ranolazine in Type 2 Diabetes Mellitus: Data from an in vivo Model. <i>Nutrients</i> , 2020, 12, 382.	4.1	34
30	Safety profile of biologic drugs for psoriasis in clinical practice: An Italian prospective pharmacovigilance study. <i>PLoS ONE</i> , 2020, 15, e0241575.	2.5	38
31	Quercetin-Oleate Contributes to Skin Wound Healing Targeting FFA1/GPR40. <i>ChemistrySelect</i> , 2019, 4, 8429-8433.	1.5	23
32	Microbiota-gut brain axis involvement in neuropsychiatric disorders. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 1037-1050.	2.8	116
33	Can we "seize" the gut microbiota to treat epilepsy?. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 107, 750-764.	6.1	60
34	Immediate and controlled-release pregabalin for the treatment of epilepsy. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 1167-1177.	2.8	6
35	Evaluation of the effects of liraglutide on the development of epilepsy and behavioural alterations in two animal models of epileptogenesis. <i>Brain Research Bulletin</i> , 2019, 153, 133-142.	3.0	24
36	Intestinal inflammation increases convulsant activity and reduces antiepileptic drug efficacy in a mouse model of epilepsy. <i>Scientific Reports</i> , 2019, 9, 13983.	3.3	51

#	ARTICLE	IF	CITATIONS
37	Cognitive impairment in the WAG/Rij rat absence model is secondary to absence seizures and depressive-like behavior. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 94, 109652.	4.8	32
38	Antiepileptogenic effects of Ethosuximide and Levetiracetam in WAG/Rij rats are only temporary. <i>Pharmacological Reports</i> , 2019, 71, 833-838.	3.3	18
39	Pharmacology of epileptogenesis and related comorbidities in the WAG/Rij rat model of genetic absence epilepsy. <i>Journal of Neuroscience Methods</i> , 2018, 310, 54-62.	2.5	26
40	Perampanel chronic treatment does not induce tolerance and decreases tolerance to clobazam in genetically epilepsy prone rats. <i>Epilepsy Research</i> , 2018, 146, 94-102.	1.6	3
41	Role of Histone Deacetylases (HDACs) in Epilepsy and Epileptogenesis. <i>Current Pharmaceutical Design</i> , 2018, 23, 5546-5562.	1.9	36
42	Genetically epilepsy-prone rats (GEPRs) and DBA/2 mice: Two animal models of audiogenic reflex epilepsy for the evaluation of new generation AEDs. <i>Epilepsy and Behavior</i> , 2017, 71, 165-173.	1.7	35
43	Liraglutide prevents cognitive decline in a rat model of streptozotocin-induced diabetes independently from its peripheral metabolic effects. <i>Behavioural Brain Research</i> , 2017, 321, 157-169.	2.2	77
44	Cerebral small vessel disease predisposes to temporal lobe epilepsy in spontaneously hypertensive rats. <i>Brain Research Bulletin</i> , 2017, 130, 245-250.	3.0	18
45	Perampanel effects in the WAG/Rij rat model of epileptogenesis, absence epilepsy, and comorbid depressive-like behavior. <i>Epilepsia</i> , 2017, 58, 231-238.	5.1	48
46	The preclinical discovery and development of brivaracetam for the treatment of focal epilepsy. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 1169-1178.	5.0	16
47	The potential role of cannabinoids in epilepsy treatment. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 1069-1079.	2.8	23
48	Fingolimod Exerts only Temporary Antiepileptogenic Effects but Longer-Lasting Positive Effects on Behavior in the WAG/Rij Rat Absence Epilepsy Model. <i>Neurotherapeutics</i> , 2017, 14, 1134-1147.	4.4	32
49	The Sphingosine 1-Phosphate Signaling Pathway in Epilepsy: A Possible Role for the Immunomodulator Drug Fingolimod in Epilepsy Treatment. <i>CNS and Neurological Disorders - Drug Targets</i> , 2017, 16, 311-325.	1.4	9
50	mTOR Signaling in Epilepsy and Epileptogenesis. , 2016, , 123-142.		4
51	The Anticonvulsant Activity of a Flavonoid-Rich Extract from Orange Juice Involves both NMDA and GABA-Benzodiazepine Receptor Complexes. <i>Molecules</i> , 2016, 21, 1261.	3.8	43
52	mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis. <i>Pharmacological Research</i> , 2016, 107, 333-343.	7.1	144
53	Upholding WAG/Rij rats as a model of absence epileptogenesis: Hidden mechanisms and a new theory on seizure development. <i>Neuroscience and Biobehavioral Reviews</i> , 2016, 71, 388-408.	6.1	77
54	Pharmacokinetic-pharmacodynamic influence of N-palmitoylethanolamine, arachidonyl-2-chloroethylamide and WIN 55,212-2 on the anticonvulsant activity of antiepileptic drugs against audiogenic seizures in DBA/2 mice. <i>European Journal of Pharmacology</i> , 2016, 791, 523-534.	3.5	23

#	ARTICLE	IF	CITATIONS
55	Palmitoylethanolamide protects mice against 6-OHDA-induced neurotoxicity and endoplasmic reticulum stress: In vivo and in vitro evidence. <i>Pharmacological Research</i> , 2016, 113, 276-289.	7.1	48
56	Everolimus improves memory and learning while worsening depressive- and anxiety-like behavior in an animal model of depression. <i>Journal of Psychiatric Research</i> , 2016, 78, 1-10.	3.1	28
57	Effects of chronic sodium alendronate on depression and anxiety in a menopausal experimental model. <i>Pharmacology Biochemistry and Behavior</i> , 2015, 129, 65-71.	2.9	25
58	Antiepileptogenic effects of the selective COX-2 inhibitor etoricoxib, on the development of spontaneous absence seizures in WAG/Rij rats. <i>Brain Research Bulletin</i> , 2015, 113, 1-7.	3.0	55
59	Antidepressants but not antipsychotics have antiepileptogenic effects with limited effects on comorbid depressive-like behaviour in the WAG/Rij rat model of absence epilepsy. <i>British Journal of Pharmacology</i> , 2015, 172, 3177-3188.	5.4	46
60	Comparative Analysis of the Treatment of Chronic Antipsychotic Drugs on Epileptic Susceptibility in Genetically Epilepsy-prone Rats. <i>Neurotherapeutics</i> , 2015, 12, 250-262.	4.4	22
61	Are big potassium-type Ca <sup>2+</sup> -activated potassium channels a viable target for the treatment of epilepsy?. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 911-926.	3.4	14
62	Perspectives on treatment options for mesial temporal lobe epilepsy with hippocampal sclerosis. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2355-2371.	1.8	33
63	Peroxisome proliferator-activated receptor alpha plays a crucial role in behavioral repetition and cognitive flexibility in mice. <i>Molecular Metabolism</i> , 2015, 4, 528-536.	6.5	48
64	Long-term betamethasone 21-phosphate disodium treatment has distinct effects in CD1 and DBA/2 mice on animal behavior accompanied by opposite effects on neurogenesis. <i>Behavioural Brain Research</i> , 2015, 278, 155-166.	2.2	8
65	Targeting $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazole-propionate receptors in epilepsy. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 319-334.	3.4	40
66	Early molecular and behavioral response to lipopolysaccharide in the WAG/Rij rat model of absence epilepsy and depressive-like behavior, involves interplay between AMPK, AKT/mTOR pathways and neuroinflammatory cytokine release. <i>Brain, Behavior, and Immunity</i> , 2014, 42, 157-168.	4.1	84
67	Protective effects of some statins on epileptogenesis and depressive-like behavior in WAG/Rij rats, a genetic animal model of absence epilepsy. <i>Epilepsia</i> , 2014, 55, 1284-1291.	5.1	54
68	The mTOR signaling pathway and neuronal stem/progenitor cell proliferation in the hippocampus are altered during the development of absence epilepsy in a genetic animal model. <i>Neurological Sciences</i> , 2014, 35, 1793-1799.	1.9	25
69	Perspective on the use of perampanel and intravenous carbamazepine for generalized seizures. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 637-644.	1.8	13
70	Pazopanib a tyrosine kinase inhibitor with strong anti-angiogenetic activity: A new treatment for metastatic soft tissue sarcoma. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 89, 322-329.	4.4	57
71	Antiepileptic action of N-palmitoylethanolamine through CB1 and PPAR- $\alpha$ receptor activation in a genetic model of absence epilepsy. <i>Neuropharmacology</i> , 2013, 69, 115-126.	4.1	91
72	mTOR inhibition modulates epileptogenesis, seizures and depressive behavior in a genetic rat model of absence epilepsy. <i>Neuropharmacology</i> , 2013, 69, 25-36.	4.1	107

#	ARTICLE	IF	CITATIONS
73	Pharmacodynamic potentiation of antiepileptic drugs's effects by some HMG-CoA reductase inhibitors against audiogenic seizures in DBA/2 mice. <i>Pharmacological Research</i> , 2013, 70, 1-12.	7.1	49
74	CB1 agonists, locally applied to the cortico-thalamic circuit of rats with genetic absence epilepsy, reduce epileptic manifestations. <i>Epilepsy Research</i> , 2013, 106, 74-82.	1.6	46
75	Lamotrigine positively affects the development of psychiatric comorbidity in epileptic animals, while psychiatric comorbidity aggravates seizures. <i>Epilepsy and Behavior</i> , 2013, 28, 232-240.	1.7	30
76	Ameliorating effects of aripiprazole on cognitive functions and depressive-like behavior in a genetic rat model of absence epilepsy and mild-depression comorbidity. <i>Neuropharmacology</i> , 2013, 64, 371-379.	4.1	72
77	Vertigo/dizziness as a Drugs' adverse reaction. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2013, 4, S104-S109.	0.4	49
78	Pharmacovigilance in pharmaceutical companies: An overview. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2013, 4, S33-S37.	0.4	25
79	Does antiepileptogenesis affects sleep in genetic epileptic rats?. <i>International Journal of Psychophysiology</i> , 2012, 85, 49-54.	1.0	11
80	Fosinopril and zofenopril, two angiotensin-converting enzyme (ACE) inhibitors, potentiate the anticonvulsant activity of antiepileptic drugs against audiogenic seizures in DBA/2 mice. <i>Pharmacological Research</i> , 2012, 65, 285-296.	7.1	37
81	New AMPA antagonists in epilepsy. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 1371-1389.	4.1	52
82	The mTOR Signaling Pathway in the Brain: Focus on Epilepsy and Epileptogenesis. <i>Molecular Neurobiology</i> , 2012, 46, 662-681.	4.0	85
83	Vigabatrin has antiepileptogenic and antidepressant effects in an animal model of epilepsy and depression comorbidity. <i>Behavioural Brain Research</i> , 2011, 225, 373-376.	2.2	43
84	Effects of early long-term treatment with antiepileptic drugs on development of seizures and depressive-like behavior in a rat genetic absence epilepsy model. <i>Epilepsia</i> , 2011, 52, 1341-1350.	5.1	71
85	Preclinical activity profile of Î±-lactalbumin, a whey protein rich in tryptophan, in rodent models of seizures and epilepsy. <i>Epilepsy Research</i> , 2011, 95, 60-69.	1.6	41
86	Comparison of the antiepileptogenic effects of an early long-term treatment with ethosuximide or levetiracetam in a genetic animal model of absence epilepsy. <i>Epilepsia</i> , 2010, 51, 1560-1569.	5.1	75
87	Palmitoylethanolamide modulates pentobarbital-evoked hypnotic effect in mice. <i>European Neuropsychopharmacology</i> , 2010, 20, 195-206.	0.7	37
88	Altered distribution and function of A <sub>2A</sub> adenosine receptors in the brain of WAG/Rij rats with genetic absence epilepsy, before and after appearance of the disease. <i>European Journal of Neuroscience</i> , 2009, 30, 1023-1035.	2.6	43
89	Solution-phase parallel synthesis and evaluation of anticonvulsant activity of N-substituted-3,4-dihydroisoquinoline-2(1H)-carboxamides. <i>European Journal of Medicinal Chemistry</i> , 2009, 44, 1349-1354.	5.5	12
90	Development of 3-substituted-1H-indole derivatives as NR2B/NMDA receptor antagonists. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 1640-1647.	3.0	34

#	ARTICLE	IF	CITATIONS
91	T-type channel blocking properties and antiabsence activity of two imidazo[1,2-b]pyridazine derivatives structurally related to indomethacin. <i>Neuropharmacology</i> , 2009, 56, 637-646.	4.1	29
92	Synthesis and anticonvulsant evaluation of N-substituted isoquinoline AMPA receptor antagonists. <i>Biorganic and Medicinal Chemistry</i> , 2008, 16, 2379-2384.	3.0	12
93	Effects of ethanol on the development of genetically determined epilepsies in rats. <i>International Journal of Developmental Neuroscience</i> , 2008, 26, 739-744.	1.6	14
94	Enhancement of anti-absence effects of ethosuximide by low doses of a noncompetitive $\hat{\pm}$ -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist in a genetic animal model of absence epilepsy. <i>Epilepsy and Behavior</i> , 2008, 13, 295-299.	1.7	20
95	Novel Potent Anticonvulsant Agent Containing a Tetrahydroisoquinoline Skeleton. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 5618-5622.	6.4	32
96	Effects of some neurosteroids injected into some brain areas of WAG/Rij rats, an animal model of generalized absence epilepsy. <i>Neuropharmacology</i> , 2006, 50, 1059-1071.	4.1	41
97	Effects of non-competitive AMPA receptor antagonists injected into some brain areas of WAG/Rij rats, an animal model of generalized absence epilepsy. <i>Neuropharmacology</i> , 2006, 51, 1058-1067.	4.1	33
98	Amino acid levels in some brain areas of inducible nitric oxide synthase knock out mouse (iNOS $\hat{\sim}$ / $\hat{\sim}$ ) before and after pentylenetetrazole kindling. <i>Pharmacology Biochemistry and Behavior</i> , 2006, 85, 804-812.	2.9	24
99	3D Pharmacophore Models for 1,2,3,4-Tetrahydroisoquinoline Derivatives Acting as Anticonvulsant Agents. <i>Archiv Der Pharmazie</i> , 2006, 339, 388-400.	4.1	18
100	Antiabsence effects of carbenoxolone in two genetic animal models of absence epilepsy (WAG/Rij rats) Tj ETQq0 0 0 rgBT /Overlock 10 T	4.1	51
101	Nifedipine affects the anticonvulsant activity of topiramate in various animal models of epilepsy. <i>Neuropharmacology</i> , 2004, 46, 865-878.	4.1	75